Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial

Abstract

Background African American accrual to prevention trials at rates representative of the disease burden experienced by this population requires additional resources and focused efforts.

Purpose To describe the rationale, context, and criteria for selection of sites that received Minority Recruitment Enhancement Grants (MREGs) to increase African American recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). To determine if African American accrual was higher among the 15 MREG sites when compared with similar nonawarded sites.

Methods Changes in African American accrual at sites that received MREGs are compared with changes in a group of 15, frequency-matched, nonawarded sites using a quasi-experimental, post hoc analysis. Successful and unsuccessful recruitment strategies reported by the MREG sites are described.

Results The increased number of African American participants accrued per month at MREG sites post-funding was higher than the change at comparison sites by a factor of 3.38 (p = 0.004, 95% CI: 1.51—7.57). An estimated 602 additional African American participants were recruited at MREG sites due to MREG funding, contributing to the overall 14.9% African American recruitment. Successful recruitment strategies most reported by MREG sites included increasing staff, transportation resources, recruiting through the media, mailings, and prostate cancer screening clinics during off-hours.

Limitations Comparison sites were chosen retrospectively, not by randomization. Although comparison sites were selected to be similar to MREG sites with regard to potential confounding factors, it is possible that unknown factors could have biased results. Cost-effective analyses were not conducted.

Conclusions MREG sites increased African American accrual in the post-funding period more than comparison sites, indicating MREG funding enhanced the sites’ abilities to accrue African American participants. Targeted grants early in the accrual period may be a useful multi-site intervention to increase African American accrual for a prevention study where adequate African American representation is essential. Clinical Trials 2010; 7: 90—99. http://ctj.sagepub.com

Get full access to this article

View all access options for this article.

References

American Cancer Society. Cancer Facts and Figures 2008. American Cancer Society, Atlanta, GA, 2008. Available at: http://www.cancer.org/docroot/stt/content/stt_1x_cancer_facts_and_figures_2008.asp (accessed 25 March 2009).

American Cancer Society. Cancer Facts and Figures for African American 2009-2010. American Cancer Society, Atlanta, GA, 2009. Available at: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_Figures_for_African_Americans_2009-2010_09.asp (accessed 25 March 2009).

Ries LAG , Melbert D. , Krapcho M. , et al. SEER Cancer Statistics Review, 1975-2004 , National Cancer Institute. Bethesda, MD Available at: http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER website , 2007 (accessed 14 December 2007).

Thompson IM , Tangen CM , Klein EA , Lippman SM

Phase III prostate cancer prevention trials: are the costs justified?

J Clin Oncol 2005; 23: 8161-4.

Feigl P. , Blumenstein B. , Thompson I. , et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995; 16: 150-63.

Moinpour CM , Atkinson JO , Thomas SM , et al. Minority recruitment in the prostate cancer prevention trial . Ann Epidemiol 2000; 10: S85-91.

Reynolds T. PCPT update: enrollment mounts, but minority participation lags. J Natl Cancer Inst 1994; 86: 1500-1.

Coltman CA , Thompson IM , Feigl P. Prostate Cancer Prevention Trial (PCPT) update. Eur Urol 1999; 35: 544-7.

Swanson GM , Ward AJ Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995; 87: 1747-59.

10.

Woods VD , Montgomery SB , Herring RP Recruiting black/African American men for research on prostate cancer prevention . Cancer 2004; 100: 1017-25.

11.

McCaskill-Stevens W. , Pinto H. , Marcus AC , et al. Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association . J Clin Oncol 1999; 17: 1029-39.

12.

Harris Y. , Gorelick PB , Samuels P. , Bempong I. Why African Americans may not be participating in clinical trials . J Natl Med Assoc 1996; 88: 630-4.

13.

Millon-Underwood S. , Sanders E. , Davis M. Determinants of participation in state-of-the-art cancer prevention, early detection screening, and treatment trials among African-Americans . Cancer Nurs 1993; 16: 25-33.

14.

Green BL , Partridge EE , Fouad MN , et al. African-American attitudes regarding cancer clinical trials and research studies: results from focus group methodology. Ethn Dis 2000; 10: 76-86.

15.

Probstfield JL , Wittes JT , Hunninghake DB Recruitment in NHLBI population-based studies and clinical trials: data analysis and survey results . Control Clin Trials 1987; 8: 141S-9S.

16.

Paskett ED , DeGraffinreid CR , Tatum CM , Margitic SE The recruitment of African-Americans to cancer prevention and control studies . Prev Med 1996; 25: 547-53.

17.

Probstfield JL The clinical trial pre-randomization compliance (adherence) screen. In: Cramer JA , Spilker B. (eds). Patient Compliance in Medical Practice and Clinical Trials. Raven Press, New York, 1991, pp. 323-34.

18.

Lippman SM , Goodman PJ , Klein EA , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005; 97: 94-102.

19.

Oddone EZ , Olsen MK , Lindquist JH , et al. Enrollment in clinical trials according to patient’s race: experience from the VA Cooperative Studies Program (1975-2000). Control Clin Trials 2004; 25: 378-87.

20.

Cook ED , Moody-Thomas S. , Anderson KB , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clin Trials 2005; 2: 436-42.